Dianthus Therapeutics, Inc.
DNTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001690585
In the last 90 days, Dianthus Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 269 institutions reported holding it in 13F filings for Q2 2026, worth $6.40B in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Dianthus Therapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Of which not filed for Q3 2022 | Q3 2022 | Change |
|---|---|---|---|---|
| Holders | 75 | 2 | 72 | −1 |
| Shares | 45.5M | 12.0K | 46.6M | +1.10M (+2.4%) |
| Value | $54.6M | $15.0K | $65.8M | +$11.2M (+20.5%) |
2 institutions that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (8)
Institutions that held Dianthus Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ra Capital Management, L.P. | 3,588,081 | $5.06M | 0.11% |
| Citadel Advisors LLC | 40,259 | $56.0K | 0.00% |
| Charles Schwab Investment Management Inc | 27,369 | $39.0K | 0.00% |
| Balyasny Asset Management LLC | 12,173 | $17.0K | 0.00% |
| UBS Group AG | 8,264 | $12.0K | 0.00% |
| Axiom Investment Management LLC | 500 | $1.00K | 0.00% |
| China Universal Asset Management Co., Ltd. | 551 | $1.00K | 0.00% |
| Allworth Financial LP | 325 | $0 | 0.00% |
Sold out (9)
Institutions that held Dianthus Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Federated Hermes, Inc. | 189,312 | $227.0K |
| First Trust Advisors LP | 55,275 | $66.0K |
| D. E. Shaw & Co., Inc. | 53,026 | $64.0K |
| Susquehanna International Group, LLP | 45,968 | $55.0K |
| Crestline Management, LP | 26,134 | $31.0K |
| Cubist Systematic Strategies, LLC | 10,667 | $13.0K |
| Y-Intercept (Hong Kong) Ltd | 10,752 | $13.0K |
| Legal & General Group Plc | 2,389 | $3.00K |
| New York State Common Retirement Fund | 244 | $0 |
Not filed for Q3 2022 yet (2)
Institutions that held Dianthus Therapeutics, Inc. at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| B. Riley Wealth Management, Inc. | 10,700 | $13.0K |
| Brewin Dolphin Wealth Management Ltd | 1,300 | $2.00K |